The most frequent tumor-infiltrating clonotypes were readily identifiable in the blood and after anti-PD1 CBI, regardless of clinical response [91]; some of them showed a Ki67+ (HLA-DR+CD38+) T exhausted phenotype, supporting the notion that T exhausted cells in the blood are reinvigorated by anti-PD-1 therapy and contain T-cell clones that are also present in the tumor [91]. This evidence concerns the gene CD38 and neoplasm.